Table 2.

Examples of active basket trials matching patients to therapies based on molecular profiles

Program nameLead organizationDesignHistologyIndication# Expected to accruePrimary outcome measure(s)Clinicaltrials.gov identifier
CREATEEORTCNRALK/MET activated advanced solid tumorsMetastatic582ORRNCT01524926
IMPACT IIMD AndersonRAdvanced solid tumorsMetastatic1,362PFSNCT02152254
My PathwayGenentechNRAdvanced solid tumorsMetastatic500ORRNCT02091141
SHIVAInstitut CurieRAdvanced solid tumorsMetastatic1,000PFSNCT01771458
SIGNATURENovartisNRPI3K-activated solid tumors and/or hematologic malignanciesMetastatic145CBRNCT01833169
BRAFV600-mutated solid tumors and/or hematologic malignanciesMetastatic12CBRNCT01981187
PTCH1 or SMO mutated solid tumors and/or hematologic malignanciesMetastatic10CBRNCT02002689
RAS/RAF/MEK activated solid tumors and/or hematologic malignanciesMetastatic110CBRNCT01885195
CDK4/6 pathway activated solid tumors and/or hematologic malignanciesMetastatic90CBRNCT02187783
FGFR mutated solid tumors and/or hematologic malignanciesMetastatic70CBRNCT02160041
ALK or ROS1 mutated solid tumors and/or hematologic malignanciesMetastatic70CBRNCT02186821
Solid tumors and/or hematologic malignancies with aberrations in FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk, or RETMetastatic80CBRNCT01831726
SPECTAEORTCNRAdvanced colorectal cancerMetastatic2,600TMA (screening)NCT01723969
Thoracic tumorsAny stage3,500TMA (screening)NCT02214134
Brain neoplasmsAny stage300TMA (screening)NCT02307604
VE-BASKETHoffmann-La RocheNRBRAFV600E-mutated advanced solid tumorsMetastatic160ORRNCT01524978
WINTHERWIN ConsortiumNRAdvanced solid tumorsMetastatic200PFSNCT01856296
Dabrafenib and trametinib in BRAFV600E-mutated rare cancersGlaxoSmithKlineNRBRAFV600E mutation–positive tumor: including anaplastic thyroid cancer, biliary tract cancer, gastrointestinal stromal tumor, nonseminomatous germ cell tumor/nonseminomatous germ cell tumor, hairy cell leukemia, WHO grade 1 or 2 glioma, WHO grade 3 or 4 (high-grade) glioma, multiple myeloma, and adenocarcinoma of the small intestineAdvanced disease without standard treatment options135ORRNCT02034110

Abbreviations: CBR, rate of clinical benefit; ECOG-ACRIN, Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network; EORTC, European Organization for Research and Treatment of Cancer; NCTN, National Clinical Trials Network; NR, nonrandomized; NSCLC, non–small cell lung cancer; ORR, overall response rate; PFS, progression-free survival; R, randomized; TMA, tumor marker assessment; WIN, worldwide innovative networking.